ALLR · Allarity Therapeutics, Inc.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date.

Restricted stock units convert into common stock on a one-for-one basis.

Restricted stock units convert into common stock on a one-for-one basis.

On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date.

The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date.

The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversay of the grant and are exercisable beginning as of that date.

The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date.

The restricted stock units, or RSUs, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The restricted stock units, or RSUs, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The restricted stock units, or RSUs, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The Reporting Person was granted 118,483 restricted stock units, or RSUs, in connection with the Reporting Person's appointment as President and Chief Development Officer of the Issuer. The RSUs will vest in equal one-third installments on the first, second, and third anniversary of the Reporting Person's appointment, subject to the Reporting Person's continued relationship with the Issuer through each such date.